Viktor Lvovich Tsepelev
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Viktor Lvovich Tsepelev has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Viktoriia V. Kriukova
Chita State Medical Academy
7 shared publications - Pavel P. Tereshkov
Chita State Medical Academy
6 shared publications - Andrey Valerevich Chetveryakov
Chita State Medical Academy
2 shared publications - A. A. Mironov
Chita State Medical Academy
1 shared publication - A. V. Sebaochzhay
Chita State Medical Academy
1 shared publication P. P. Tereshkov
Chita State Medical Academy
1 shared publication
Latest Publications
- Open Access
- 30 July 2026
- Published by Chita State Medical Academy in Transbaikalian Medical Bulletin
- No. 2,p. 162-174
T-LYMPHOCYTE SUBPOPULATIONS IN COLORECTAL CANCER
This review summarizes current data on the composition, functional state, and role of T-lymphocyte subpopulations engaged in the antitumour immune response in patients with colorectal carcinoma. The distinct functional states of CD8+, CD4+ T-cells, regulatory T-cells (Treg), tissue-resident memory T-cells (TRM) and unconventional lymphocyte populations- including invariant natural killer (iNKT) and γδ-T-cells- are examined within the colorectal tumour microenvironment. It has been shown that a prevalence of CD8+ and Th1 cells is associated with a favorable prognosis, whereas functional exhaustion of T cells with co-expression of PD-1, TIM-3, LAG-3, and TIGIT reflects immune dysfunction and may indicate disease progression. A context-dependent influence of Th2 and Th17 cells has been noted. The functional exhaustion of tissue-resident memory CD8+ Trm cells in the tumor microenvironment during disease progression is described. This review demonstrates that the immune landscape of colorectal cancer is shaped by the interplay of diverse T-lymphocyte subpopulations driven by their functional and quantitative heterogeneity, thereby underscoring the significance of these characteristics for the development of prognostic biomarkers and personalized immunotherapeutic strategies.
- 30 July 2026
- Published by Chita State Medical Academy in Transbaikalian Medical Bulletin
- No. 2,p. 162-174
Open AccessT-LYMPHOCYTE SUBPOPULATIONS IN COLORECTAL CANCER
This review summarizes current data on the composition, functional state, and role of T-lymphocyte subpopulations engaged in the antitumour immune response in patients with colorectal carcinoma. The distinct functional states of CD8+, CD4+ T-cells, regulatory T-cells (Treg), tissue-resident memory T-cells (TRM) and unconventional lymphocyte populations- including invariant natural killer (iNKT) and γδ-T-cells- are examined within the colorectal tumour microenvironment. It has been shown that a prevalence of CD8+ and Th1 cells is associated with a favorable prognosis, whereas functional exhaustion of T cells with co-expression of PD-1, TIM-3, LAG-3, and TIGIT reflects immune dysfunction and may indicate disease progression. A context-dependent influence of Th2 and Th17 cells has been noted. The functional exhaustion of tissue-resident memory CD8+ Trm cells in the tumor microenvironment during disease progression is described. This review demonstrates that the immune landscape of colorectal cancer is shaped by the interplay of diverse T-lymphocyte subpopulations driven by their functional and quantitative heterogeneity, thereby underscoring the significance of these characteristics for the development of prognostic biomarkers and personalized immunotherapeutic strategies.
- 7 April 2026
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 25 (1)
Cancer stem cells in colorectal cancer
Background . Cancer stem cells (CSCs) are considered to be responsible for progression and recurrence of colorectal cancer (CRC). A detailed study of the phenotype of these cells and their immunobiological properties is necessary for developing CRC treatments. The aim of the study was to assess the percentage of EpCAM high /CD44 + cancer stem cells in colorectal cancer and to detect the expression of CD133, CD166, CD24 and CD184 on their surface. Material and Methods . A one-stage cross-sectional study of the cellular composition of tumor tissue was performed in 123 patients with stage III colon adenocarcinoma. The control group consisted of 87 patients who underwent surgery for non-neoplastic diseases of the colon. An enzymatic method was used to obtain a suspension of tumor tissue cells. Gating of non-lymphoid cells (CD45-) was performed depending on the expression of the epithelial cell adhesion molecule EpCAM and the differentiation antigen CD44 on their surface. Expression of EpCAM, CD44, CD133, CD166, CD184 and CD24 on CSCs was studied by fow cytometry. Results . The CD45-EpCAM high CD44+ colorectal cancer stem cells (CSCs) accounted for 17.15 % [11.76; 26.44] of the non-lymphoid cell population. Within this CSC population, 42.83 % [37.07; 51.77] simultaneously expressed CD133 and CD166, while 57.17 % [48.23; 62.93] expressed the CD133 antigen alone. All CSCs in the primary tumor expressed CD184, and 95.18 % [88.48; 97.98] of them simultaneously expressed CD24. The percentage of EpCAM high CD44 + cells in well-differentiated tumors was 1.5 times lower than that in moderately-differentiated tumors (U=326.5, p=0.002) and 2.1 times lower than in poorly-differentiated tumors (U=21.0, phigh CD44 + CD133 + CD166 + cells in stage IIIC CRC was 13 % higher than that in stage IIIB CRC (U=1116.0, p=0.007). Conclusion . In primary colorectal cancer tumors, cancer stem cells expressing high levels of EpCAM and CD44 accounted for 17.2 % of the non-lymphoid cell pool. The percentage of EpCAM high /CD44 + cells in poorly differentiated tumors was higher than that in well-or moderately-differentiated tumors.
- 7 April 2026
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 25 (1)
Cancer stem cells in colorectal cancer
Background . Cancer stem cells (CSCs) are considered to be responsible for progression and recurrence of colorectal cancer (CRC). A detailed study of the phenotype of these cells and their immunobiological properties is necessary for developing CRC treatments. The aim of the study was to assess the percentage of EpCAM high /CD44 + cancer stem cells in colorectal cancer and to detect the expression of CD133, CD166, CD24 and CD184 on their surface. Material and Methods . A one-stage cross-sectional study of the cellular composition of tumor tissue was performed in 123 patients with stage III colon adenocarcinoma. The control group consisted of 87 patients who underwent surgery for non-neoplastic diseases of the colon. An enzymatic method was used to obtain a suspension of tumor tissue cells. Gating of non-lymphoid cells (CD45-) was performed depending on the expression of the epithelial cell adhesion molecule EpCAM and the differentiation antigen CD44 on their surface. Expression of EpCAM, CD44, CD133, CD166, CD184 and CD24 on CSCs was studied by fow cytometry. Results . The CD45-EpCAM high CD44+ colorectal cancer stem cells (CSCs) accounted for 17.15 % [11.76; 26.44] of the non-lymphoid cell population. Within this CSC population, 42.83 % [37.07; 51.77] simultaneously expressed CD133 and CD166, while 57.17 % [48.23; 62.93] expressed the CD133 antigen alone. All CSCs in the primary tumor expressed CD184, and 95.18 % [88.48; 97.98] of them simultaneously expressed CD24. The percentage of EpCAM high CD44 + cells in well-differentiated tumors was 1.5 times lower than that in moderately-differentiated tumors (U=326.5, p=0.002) and 2.1 times lower than in poorly-differentiated tumors (U=21.0, phigh CD44 + CD133 + CD166 + cells in stage IIIC CRC was 13 % higher than that in stage IIIB CRC (U=1116.0, p=0.007). Conclusion . In primary colorectal cancer tumors, cancer stem cells expressing high levels of EpCAM and CD44 accounted for 17.2 % of the non-lymphoid cell pool. The percentage of EpCAM high /CD44 + cells in poorly differentiated tumors was higher than that in well-or moderately-differentiated tumors.
- 15 February 2026
- Published by Pacific State Medical University in Pacific Medical Journal
- No. 4
Cancer stem cells in metastatic lymph nodes in patients with colorectal cancer
Objective. To assess the content of cancer stem cells (CSCs) with the EpCAMhighCD44+ phenotype in metastatic lymph nodes in patients with colorectal cancer (CRC), as well as the expression of CD133, CD166, CD24, and CD184 on their surface. Materials and methods. A cross-sectional prospective study of the cellular composition of metastatic lymph nodes was performed in 123 patients with phase III CRC. The control group consisted of 87 patients who underwent surgery for non-neoplastic colon diseases. Lymph node cells were isolated by an enzymatic method. The expression of CD45, EpCAM, CD44, CD133, CD166, CD184, and CD24 on CSCs was assessed by flow cytometry using a CytoFLEX LX cytometer (Beckman Coulter, USA). Statistical analysis of the data was performed using the nonparametric Mann–Whitney U test. Results. Among metastatically affected regional lymph nodes of CRC patients, 7.6 [4.3; 11.9]% of CSC with the EpCAMhighCD44+ phenotype were found in the total population of non-lymphoid cells (CD45-). No cells with high EpCAM expression were found in the lymph nodes of patients in the control group. In metastatic lymph nodes, 50.8 [42.5; 60.1]% of CSC simultaneously express CD133 and CD166, and 49.2 [39.9; 57.5]% of cells exhibited the presence of the CD133 antigen. All CSCs in metastatic lymph nodes expressed CD184, and 94.9 [90.0; 97.7]% of them simultaneously contained CD24. Conclusion. Highly EpCAM-expressing CSCs can be found in metastatically affected regional lymph nodes in patients with stage III colorectal cancer. CD44-positive cells comprise 7.6% of nonlymphoid cells. The CXC type 4 chemokine receptor (CD184) and CD133 protein are markers of CSCs in CRC.
- 15 February 2026
- Published by Pacific State Medical University in Pacific Medical Journal
- No. 4
Cancer stem cells in metastatic lymph nodes in patients with colorectal cancer
Objective. To assess the content of cancer stem cells (CSCs) with the EpCAMhighCD44+ phenotype in metastatic lymph nodes in patients with colorectal cancer (CRC), as well as the expression of CD133, CD166, CD24, and CD184 on their surface. Materials and methods. A cross-sectional prospective study of the cellular composition of metastatic lymph nodes was performed in 123 patients with phase III CRC. The control group consisted of 87 patients who underwent surgery for non-neoplastic colon diseases. Lymph node cells were isolated by an enzymatic method. The expression of CD45, EpCAM, CD44, CD133, CD166, CD184, and CD24 on CSCs was assessed by flow cytometry using a CytoFLEX LX cytometer (Beckman Coulter, USA). Statistical analysis of the data was performed using the nonparametric Mann–Whitney U test. Results. Among metastatically affected regional lymph nodes of CRC patients, 7.6 [4.3; 11.9]% of CSC with the EpCAMhighCD44+ phenotype were found in the total population of non-lymphoid cells (CD45-). No cells with high EpCAM expression were found in the lymph nodes of patients in the control group. In metastatic lymph nodes, 50.8 [42.5; 60.1]% of CSC simultaneously express CD133 and CD166, and 49.2 [39.9; 57.5]% of cells exhibited the presence of the CD133 antigen. All CSCs in metastatic lymph nodes expressed CD184, and 94.9 [90.0; 97.7]% of them simultaneously contained CD24. Conclusion. Highly EpCAM-expressing CSCs can be found in metastatically affected regional lymph nodes in patients with stage III colorectal cancer. CD44-positive cells comprise 7.6% of nonlymphoid cells. The CXC type 4 chemokine receptor (CD184) and CD133 protein are markers of CSCs in CRC.
- 30 December 2025
- Published by LLC Science and Innovations in Saratov Journal of Medical Scientific Research
- Vol. 21 (4)
Regulatory T lymphocytes in regional lymph nodes of patients with colorectal cancer
Objective: to identify changes in the regulatory T cell (Treg) pool and the expression level of inducible T-cell costimulator (ICOS) and programmed cell death protein (PD-1) on their membrane in metastatic lymph nodes in colorectal cancer (CC). Material and methods. The main group consisted of 105 patients with stage III CC. The clinical comparison group consisted of non-neoplastic pathology (developmental anomalies, stomas, diverticular disease of the colon). The Treg pool and the expression of PD-1 and ICOS were studied using flow cytometry. Results. In metastatic lymph nodes with RTC, the content of Treg increases by 3.5 times (p<0.001), the relative number of naive Treg decreases (p<0.001), the number of central memory Treg expressing CD197 on their membrane increases almost 2 times (p<0.001), and effector memory cells with the CD45RA–CD197– phenotype increase 3.6 times (p<0.001). The number of PD-1−ICOS+ Treg in the total population of CD3+ lymphocytes increases by 3.1 times (p<0.001). The number of Treg with the CD19−CD3+CD4+CD25highCD127−PD-1+ICOS+ phenotype increases by 1.5 times (p<0.001) compared to the control. Conclusion. In patients with RTC, the number of naive Treg in metastatically affected lymph nodes decreases, the relative content of central and effector memory Treg increases, the number of Treg expressing ICOS increases, as well as those simultaneously expressing both the inhibitory protein PD-1 and the stimulating molecule ICOS.
- 30 December 2025
- Published by LLC Science and Innovations in Saratov Journal of Medical Scientific Research
- Vol. 21 (4)
Regulatory T lymphocytes in regional lymph nodes of patients with colorectal cancer
Objective: to identify changes in the regulatory T cell (Treg) pool and the expression level of inducible T-cell costimulator (ICOS) and programmed cell death protein (PD-1) on their membrane in metastatic lymph nodes in colorectal cancer (CC). Material and methods. The main group consisted of 105 patients with stage III CC. The clinical comparison group consisted of non-neoplastic pathology (developmental anomalies, stomas, diverticular disease of the colon). The Treg pool and the expression of PD-1 and ICOS were studied using flow cytometry. Results. In metastatic lymph nodes with RTC, the content of Treg increases by 3.5 times (p<0.001), the relative number of naive Treg decreases (p<0.001), the number of central memory Treg expressing CD197 on their membrane increases almost 2 times (p<0.001), and effector memory cells with the CD45RA–CD197– phenotype increase 3.6 times (p<0.001). The number of PD-1−ICOS+ Treg in the total population of CD3+ lymphocytes increases by 3.1 times (p<0.001). The number of Treg with the CD19−CD3+CD4+CD25highCD127−PD-1+ICOS+ phenotype increases by 1.5 times (p<0.001) compared to the control. Conclusion. In patients with RTC, the number of naive Treg in metastatically affected lymph nodes decreases, the relative content of central and effector memory Treg increases, the number of Treg expressing ICOS increases, as well as those simultaneously expressing both the inhibitory protein PD-1 and the stimulating molecule ICOS.
- Open Access
- 14 December 2025
- Published by Publishing House ABV Press in Advances in molecular oncology
- Vol. 12 (4) , 100-108
Regulatory T cells in the primary tumor growth lesion in colorectal cancer
Introduction. Regulatory T cells (Treg) have pro-oncogenic activity, inhibit the immune response and therefore can be a significant target for immunotherapeutic methods of treating colorectal cancer (CRC). Currently, the role of regulatory T cells in the mechanisms of carcinogenesis, as well as the participation of co-inhibitory and co-stimulating proteins of the immune system in the formation of tumor immunosuppression in CRC, is insufficiently studied. Aim. To determine the content of Treg subtypes in the primary tumor focus in patients with CRC and to evaluate the expression level of co-stimulating and co-inhibitory proteins on their membrane. Materials and methods. The main group consisted of 105 patients with stage III colon adenocarcinoma; the control group – 75 patients with non-neoplastic diseases of the colon. The object of the study was tumor-infiltrating T lymphocytes, which were isolated by an enzymatic method. Determination of Treg subtypes, as well as expression of programmed cell death 1 (PD-1) and inducible T-cell costimulator (ICOS) proteins, was performed by flow cytometry. Treg was identified as CD19−CD3+CD4+CD25highCD127−. Based on the expression of CD45RA and CD197, Treg subtypes were determined as naive (CD45RA+CD197+), central memory (CD45RA–CD197+), effector memory (CD45RA–CD197–), and terminally differentiated (CD45RA+CD197–). The significance of differences in the parameters of the main and control groups was assessed using the nonparametric Mann–Whitney U test. Results. In the primary focus of tumor growth in CRC, the content of Treg increases by 4.4 times. At the same time, the ratio of Treg subtypes in the tumor microenvironment changes, which is expressed in a 1.4-fold decrease in the number of naive cells, as well as a 2.8-fold increase in the number of effector memory Treg and a 3.1-fold increase in terminally differentiated lymphocytes. Tumor-infiltrating Treg expressed the ICOS 2 times more strongly compared to the control. A 20 % increase in the number of Treg PD-1+ICOS+ was established. The number of Treg PD-1−ICOS− cells in the primary tumor focus decreased by 1.4 times compared to the control group. Conclusion. In patients with CRC, the number of naive Treg decreases in the primary tumor focus and the relative content of differentiated effector cells increases. In the tumor microenvironment in CRC, the number of Tregs increases, expressing on their surface both the costimulating molecule ICOS and the co-inhibitory receptor PD-1.
- 14 December 2025
- Published by Publishing House ABV Press in Advances in molecular oncology
- Vol. 12 (4) , 100-108
Open AccessRegulatory T cells in the primary tumor growth lesion in colorectal cancer
Introduction. Regulatory T cells (Treg) have pro-oncogenic activity, inhibit the immune response and therefore can be a significant target for immunotherapeutic methods of treating colorectal cancer (CRC). Currently, the role of regulatory T cells in the mechanisms of carcinogenesis, as well as the participation of co-inhibitory and co-stimulating proteins of the immune system in the formation of tumor immunosuppression in CRC, is insufficiently studied. Aim. To determine the content of Treg subtypes in the primary tumor focus in patients with CRC and to evaluate the expression level of co-stimulating and co-inhibitory proteins on their membrane. Materials and methods. The main group consisted of 105 patients with stage III colon adenocarcinoma; the control group – 75 patients with non-neoplastic diseases of the colon. The object of the study was tumor-infiltrating T lymphocytes, which were isolated by an enzymatic method. Determination of Treg subtypes, as well as expression of programmed cell death 1 (PD-1) and inducible T-cell costimulator (ICOS) proteins, was performed by flow cytometry. Treg was identified as CD19−CD3+CD4+CD25highCD127−. Based on the expression of CD45RA and CD197, Treg subtypes were determined as naive (CD45RA+CD197+), central memory (CD45RA–CD197+), effector memory (CD45RA–CD197–), and terminally differentiated (CD45RA+CD197–). The significance of differences in the parameters of the main and control groups was assessed using the nonparametric Mann–Whitney U test. Results. In the primary focus of tumor growth in CRC, the content of Treg increases by 4.4 times. At the same time, the ratio of Treg subtypes in the tumor microenvironment changes, which is expressed in a 1.4-fold decrease in the number of naive cells, as well as a 2.8-fold increase in the number of effector memory Treg and a 3.1-fold increase in terminally differentiated lymphocytes. Tumor-infiltrating Treg expressed the ICOS 2 times more strongly compared to the control. A 20 % increase in the number of Treg PD-1+ICOS+ was established. The number of Treg PD-1−ICOS− cells in the primary tumor focus decreased by 1.4 times compared to the control group. Conclusion. In patients with CRC, the number of naive Treg decreases in the primary tumor focus and the relative content of differentiated effector cells increases. In the tumor microenvironment in CRC, the number of Tregs increases, expressing on their surface both the costimulating molecule ICOS and the co-inhibitory receptor PD-1.
- Open Access
- 18 July 2025
- Published by FSPSI SCFHHRP in Acta Biomedica Scientifica
- Vol. 10 (3) , 106-113
Cytotoxic T lymphocytes in regional lymph nodes in colon cancer
Background. The study of the subpopulation composition of cytotoxic T lymphocytes and the expression of co-inhibitory proteins on their surface in regional lymph nodes is necessary for the development of new methods of targeted therapy for colorectal cancer (CRC). The aim. To assess the subpopulation composition of cytotoxic T lymphocytes and the expression of co-inhibitory molecules on their surface in regional lymph nodes in patients with colon cancer. Methods. The relative content of cytotoxic T lymphocytes in regional lymph nodes, the subpopulation composition of cytotoxic T lymphocytes, and the expression of immune checkpoints (CTLA-4, PD-1, TIM-3) by CD8-positive cells in 105 patients with stage III colorectal cancer were determined using flow cytometry. The control group consisted of 75 patients who underwent colon surgery for non-neoplastic diseases. Results. In patients with CRC, the number of naive CD8+ lymphocytes (CD3+CD8+CD45RA+CCR7+) in regional lymph nodes decreases by 1.6 times, the relative content of cytotoxic T lymphocytes of effector memory (CD3+CD8+CD45RA-ССR7-) increases by 2.6 times, and the relative content of CD8-positive cells expressing CD57 on their surface increases by 2.6 times. In patients with CRC, on the surface of CD3+CD8+ lymphocytes of regional lymph nodes, the expression of the co-inhibitory molecule CTLA-4 increases by 4.5 times, PD-1 by 2.2 times, and TIM-3 protein by 1.7 times. Conclusion. In patients with colorectal cancer, the subpopulation composition of cytotoxic T lymphocytes in regional lymph nodes changes, which is expressed in a decrease in the proportion of naive cells and an increase in the relative content of effector memory cells. In CRC, the expression of co-inhibitory molecules (CTLA-4, PD-1 and TIM-3) on cytotoxic T lymphocytes in regional lymph nodes increases.
- 18 July 2025
- Published by FSPSI SCFHHRP in Acta Biomedica Scientifica
- Vol. 10 (3) , 106-113
Open AccessCytotoxic T lymphocytes in regional lymph nodes in colon cancer
Background. The study of the subpopulation composition of cytotoxic T lymphocytes and the expression of co-inhibitory proteins on their surface in regional lymph nodes is necessary for the development of new methods of targeted therapy for colorectal cancer (CRC). The aim. To assess the subpopulation composition of cytotoxic T lymphocytes and the expression of co-inhibitory molecules on their surface in regional lymph nodes in patients with colon cancer. Methods. The relative content of cytotoxic T lymphocytes in regional lymph nodes, the subpopulation composition of cytotoxic T lymphocytes, and the expression of immune checkpoints (CTLA-4, PD-1, TIM-3) by CD8-positive cells in 105 patients with stage III colorectal cancer were determined using flow cytometry. The control group consisted of 75 patients who underwent colon surgery for non-neoplastic diseases. Results. In patients with CRC, the number of naive CD8+ lymphocytes (CD3+CD8+CD45RA+CCR7+) in regional lymph nodes decreases by 1.6 times, the relative content of cytotoxic T lymphocytes of effector memory (CD3+CD8+CD45RA-ССR7-) increases by 2.6 times, and the relative content of CD8-positive cells expressing CD57 on their surface increases by 2.6 times. In patients with CRC, on the surface of CD3+CD8+ lymphocytes of regional lymph nodes, the expression of the co-inhibitory molecule CTLA-4 increases by 4.5 times, PD-1 by 2.2 times, and TIM-3 protein by 1.7 times. Conclusion. In patients with colorectal cancer, the subpopulation composition of cytotoxic T lymphocytes in regional lymph nodes changes, which is expressed in a decrease in the proportion of naive cells and an increase in the relative content of effector memory cells. In CRC, the expression of co-inhibitory molecules (CTLA-4, PD-1 and TIM-3) on cytotoxic T lymphocytes in regional lymph nodes increases.
- Open Access
- 30 May 2025
- Published by ECO-Vector LLC in Kazan medical journal
- Vol. 106 (3) , 341-348
Expression of Immune Checkpointson T-Lymphocytes in Regional Lymph Nodes in Patients With Colorectal Cancer
BACKGROUND: Investigation of immune checkpoint expression on T-lymphocytes is essential for determining immunotherapy strategies for colorectal cancer. AIM: The work aimed to examine the expression of immune checkpoints on T-lymphocytes in regional lymph nodes in patients with colorectal cancer. MATERIAL AND METHODS: Flow cytometry was used to evaluate the expression levels of immune checkpoints (CTLA-4, PD-1, TIM-3) on T-lymphocytes in regional lymph nodes in 105 patients with stage III colorectal cancer. The control group included 75 patients with nonneoplastic colon diseases. The Mann–Whitney U-test was used to compare two independent groups. ROC analysis was performed to identify diagnostic threshold values. Differences were considered statistically significant at p 0.05. RESULTS: In the regional lymph nodes of patients with colorectal cancer, CTLA-4 expression increased 7.9-fold on T-helper cells [42.9% (25.1%–59.8%) in the main group vs 5.4% (2.8%–7.8%) in controls; p 0.001], and 4.5-fold on cytotoxic T-lymphocytes [35.0% (16.9%–52.8%) vs 7.8% (3.5%–12.7%); p 0.001]. PD-1 expression increased 1.5-fold on CD4-positive T-lymphocytes [46.9 (33.5; 62.9)% in the main group vs 31.7 (18.9; 42.7)% in controls, p 0.001], and 2.2-fold on cytotoxic T-lymphocytes (p 0.001). TIM-3 expression on cytotoxic T-lymphocytes in regional lymph nodes reached 3.8 (2.3; 6.6)% in patients with colorectal cancer, exceeding the control value of 2.3 (1.5; 4.1)% by 1.7 times (p 0.001). Statistically significant threshold values for CTLA-4 expression in regional lymph nodes were established at ≥ 11.1% for T-helper cells and 20.1% for cytotoxic T-lymphocytes. CONCLUSION: In patients with colorectal cancer, the expression of the co-inhibitory receptors CTLA-4 and PD-1 is increased on both T-helper cells and cytotoxic T-lymphocytes in regional lymph nodes, whereas TIM-3 expression is elevated on CD8+ T-lymphocytes.
- 30 May 2025
- Published by ECO-Vector LLC in Kazan medical journal
- Vol. 106 (3) , 341-348
Open AccessExpression of Immune Checkpointson T-Lymphocytes in Regional Lymph Nodes in Patients With Colorectal Cancer
BACKGROUND: Investigation of immune checkpoint expression on T-lymphocytes is essential for determining immunotherapy strategies for colorectal cancer. AIM: The work aimed to examine the expression of immune checkpoints on T-lymphocytes in regional lymph nodes in patients with colorectal cancer. MATERIAL AND METHODS: Flow cytometry was used to evaluate the expression levels of immune checkpoints (CTLA-4, PD-1, TIM-3) on T-lymphocytes in regional lymph nodes in 105 patients with stage III colorectal cancer. The control group included 75 patients with nonneoplastic colon diseases. The Mann–Whitney U-test was used to compare two independent groups. ROC analysis was performed to identify diagnostic threshold values. Differences were considered statistically significant at p 0.05. RESULTS: In the regional lymph nodes of patients with colorectal cancer, CTLA-4 expression increased 7.9-fold on T-helper cells [42.9% (25.1%–59.8%) in the main group vs 5.4% (2.8%–7.8%) in controls; p 0.001], and 4.5-fold on cytotoxic T-lymphocytes [35.0% (16.9%–52.8%) vs 7.8% (3.5%–12.7%); p 0.001]. PD-1 expression increased 1.5-fold on CD4-positive T-lymphocytes [46.9 (33.5; 62.9)% in the main group vs 31.7 (18.9; 42.7)% in controls, p 0.001], and 2.2-fold on cytotoxic T-lymphocytes (p 0.001). TIM-3 expression on cytotoxic T-lymphocytes in regional lymph nodes reached 3.8 (2.3; 6.6)% in patients with colorectal cancer, exceeding the control value of 2.3 (1.5; 4.1)% by 1.7 times (p 0.001). Statistically significant threshold values for CTLA-4 expression in regional lymph nodes were established at ≥ 11.1% for T-helper cells and 20.1% for cytotoxic T-lymphocytes. CONCLUSION: In patients with colorectal cancer, the expression of the co-inhibitory receptors CTLA-4 and PD-1 is increased on both T-helper cells and cytotoxic T-lymphocytes in regional lymph nodes, whereas TIM-3 expression is elevated on CD8+ T-lymphocytes.
- Open Access
- 24 February 2025
- Published by Chita State Medical Academy in Transbaikalian Medical Bulletin
- No. 4,p. 29-35
SUBPOPULATION COMPOSITION OF T-HELPER CELLS IN THE TUMOR MICROENVIRONMENT IN COLON CANCER
Objective – to study the subpopulation composition of T-helpers in the tumor microenvironment of patients with colon cancer.Materials and methods. The relative content of T-helpers in the tumor microenvironment, the subpopulation composition of T-helpers, and the expression of co-inhibitory proteins (CTLA-4, PD-1, TIM-3) by CD4-positive cells were determined by flow cytofluorimetry in 105 patients with stage III colorectal cancer. The control group consisted of 75 patients who underwent colon surgery for non-neoplastic diseases.Results. In patients with colorectal cancer (CRC), the relative content of T-helpers in the tumor microenvironment increases by 1,4, the proportion of naive cells (CD3+CD4+CD45RA+CCR7+) decreases by 1,8 times, the relative content of central memory T-helpers (CD3+CD4+CD45RA-CCR7+) increases, the number of CD4-positive effector memory cells (CD3+CD4+CD45RA-ССR7-) and terminally differentiated T-helpers (CD3+CD4+CD45RA+ССR7-) decreases. In patients with CRC, on the surface of CD3+CD4+ lymphocytes in the tumor microenvironment, the expression of CD57 increases by 4,1 times, the co-inhibitory molecule CTLA-4 by 5,5 times, and the PD-1 protein by 1,8 times.Conclusion. In patients with colorectal cancer, the subpopulation composition of T-helpers in the tumor microenvironment changes, which is expressed in a decrease in the proportion of naive cells and the most differentiated effector cells with a simultaneous increase in the percentage of central memory cells.
- 24 February 2025
- Published by Chita State Medical Academy in Transbaikalian Medical Bulletin
- No. 4,p. 29-35
Open AccessSUBPOPULATION COMPOSITION OF T-HELPER CELLS IN THE TUMOR MICROENVIRONMENT IN COLON CANCER
Objective – to study the subpopulation composition of T-helpers in the tumor microenvironment of patients with colon cancer.Materials and methods. The relative content of T-helpers in the tumor microenvironment, the subpopulation composition of T-helpers, and the expression of co-inhibitory proteins (CTLA-4, PD-1, TIM-3) by CD4-positive cells were determined by flow cytofluorimetry in 105 patients with stage III colorectal cancer. The control group consisted of 75 patients who underwent colon surgery for non-neoplastic diseases.Results. In patients with colorectal cancer (CRC), the relative content of T-helpers in the tumor microenvironment increases by 1,4, the proportion of naive cells (CD3+CD4+CD45RA+CCR7+) decreases by 1,8 times, the relative content of central memory T-helpers (CD3+CD4+CD45RA-CCR7+) increases, the number of CD4-positive effector memory cells (CD3+CD4+CD45RA-ССR7-) and terminally differentiated T-helpers (CD3+CD4+CD45RA+ССR7-) decreases. In patients with CRC, on the surface of CD3+CD4+ lymphocytes in the tumor microenvironment, the expression of CD57 increases by 4,1 times, the co-inhibitory molecule CTLA-4 by 5,5 times, and the PD-1 protein by 1,8 times.Conclusion. In patients with colorectal cancer, the subpopulation composition of T-helpers in the tumor microenvironment changes, which is expressed in a decrease in the proportion of naive cells and the most differentiated effector cells with a simultaneous increase in the percentage of central memory cells.
- Open Access
- 30 September 2022
- Published by Kemerovo State Medical University in Fundamental and Clinical Medicine
- Vol. 7 (3) , 17-22
Pathogenetic significance of transforming growth factor β1 in patients with colorectal cancer
Aim. We aimed to evaluate levels of transforming growth factor β1 (TGF-β1) in the serum, lymph nodes, and primary tumour in patients with colorectal cancer.Materials and Methods. Here we enrolled 44 patients with colorectal cancer and 25 patients with benign tumours of the colon admitted to Chita Regional Cancer Centre in 2019-2020. The control group included 25 patients with colon injury. The concentration of TGF-β1 in the serum, lymph nodes, and tumour homogenate was measured by flow cytometry (CytoFlex LX analyzer and LEGENDplex HU multiplex analysis kit).Results. Serum level of TGF-β1 in patients with colorectal cancer was 1.58-fold lower than in those with benign colon tumours and 1.38-fold lower than in the control group. In contrast, TGF-β1 level in tumor tissue was 5.91 (3.86; 7.81) fold higher than in the injured colonic tissue from the control group, although there were no statistically significant differences between the cancerous tissue and benign neoplasms.Conclusion. TGF-β1 is increased in tumour tissue but reduced in the serum of patients with colorectal cancer.
- 30 September 2022
- Published by Kemerovo State Medical University in Fundamental and Clinical Medicine
- Vol. 7 (3) , 17-22
Open AccessPathogenetic significance of transforming growth factor β1 in patients with colorectal cancer
Aim. We aimed to evaluate levels of transforming growth factor β1 (TGF-β1) in the serum, lymph nodes, and primary tumour in patients with colorectal cancer.Materials and Methods. Here we enrolled 44 patients with colorectal cancer and 25 patients with benign tumours of the colon admitted to Chita Regional Cancer Centre in 2019-2020. The control group included 25 patients with colon injury. The concentration of TGF-β1 in the serum, lymph nodes, and tumour homogenate was measured by flow cytometry (CytoFlex LX analyzer and LEGENDplex HU multiplex analysis kit).Results. Serum level of TGF-β1 in patients with colorectal cancer was 1.58-fold lower than in those with benign colon tumours and 1.38-fold lower than in the control group. In contrast, TGF-β1 level in tumor tissue was 5.91 (3.86; 7.81) fold higher than in the injured colonic tissue from the control group, although there were no statistically significant differences between the cancerous tissue and benign neoplasms.Conclusion. TGF-β1 is increased in tumour tissue but reduced in the serum of patients with colorectal cancer.
- 1 January 2022
- Published by Russian Vrach, Publishing House Ltd. in Молекулярная медицина
- Vol. 20 (4) , 60-63
Activity of the 4-1BB/4-1BBL signaling pathway in patients with colon tumors
Введение. Белок 4-1BB (CD137) усиливает активность Т-клеток, предотвращает их гибель, а также способствует выработке цитокинов, что делает его мощным костимулирующим фактором. В настоящее время ведется изучение применения этого гликопротеина с целью воздействия на ключевые звенья канцерогенеза. Цель исследования. Оценка уровня 4-1ВВ в сыворотке крови, ткани опухоли и лимфатических узлов у больных с опухолями толстой кишки. Методы. Исследование выполнено на базе ГУЗ «Краевой онкологический диспансер» (Чита) и включало 44 пациента с колоректальным раком, а также 25 больных с доброкачественными новообразованиями толстой кишки, проходивших лечение в период с 2019 по 2020 гг. Контрольная группа включала 25 пациентов, проходивших лечение (пластика колостомы) в ГУЗ «Краевая клиническая больница» (Чита). Концентрацию 4-1BB определяли в сыворотке крови, супернатанте гомогената ткани опухоли и лимфатических узлов с помощью метода проточной цитофлуометрии. Результаты. Установлено, что у больных раком толстой кишки концентрация растворимой формы 4-1BB в сыворотке крови увеличивалась в 1,88раза, у пациентов с доброкачественными новообразованиями толстой кишки - в 1,86раза относительно контрольной группы. Концентрация 4-1BB в ткани опухоли у пациентов с колоректальным раком превышала данный показатель группы контроля в 2,06раза и группы больных с доброкачественными новообразованиями в 1,43раза. Заключение. Сигнальный путь 4-1BB/4-1BBL вовлечен в каскад реакций врожденного и адаптивного иммунитета и является одним из звеньев канцерогенеза у больных с колоректальным...
- 1 January 2022
- Published by Russian Vrach, Publishing House Ltd. in Молекулярная медицина
- Vol. 20 (4) , 60-63
Activity of the 4-1BB/4-1BBL signaling pathway in patients with colon tumors
Введение. Белок 4-1BB (CD137) усиливает активность Т-клеток, предотвращает их гибель, а также способствует выработке цитокинов, что делает его мощным костимулирующим фактором. В настоящее время ведется изучение применения этого гликопротеина с целью воздействия на ключевые звенья канцерогенеза. Цель исследования. Оценка уровня 4-1ВВ в сыворотке крови, ткани опухоли и лимфатических узлов у больных с опухолями толстой кишки. Методы. Исследование выполнено на базе ГУЗ «Краевой онкологический диспансер» (Чита) и включало 44 пациента с колоректальным раком, а также 25 больных с доброкачественными новообразованиями толстой кишки, проходивших лечение в период с 2019 по 2020 гг. Контрольная группа включала 25 пациентов, проходивших лечение (пластика колостомы) в ГУЗ «Краевая клиническая больница» (Чита). Концентрацию 4-1BB определяли в сыворотке крови, супернатанте гомогената ткани опухоли и лимфатических узлов с помощью метода проточной цитофлуометрии. Результаты. Установлено, что у больных раком толстой кишки концентрация растворимой формы 4-1BB в сыворотке крови увеличивалась в 1,88раза, у пациентов с доброкачественными новообразованиями толстой кишки - в 1,86раза относительно контрольной группы. Концентрация 4-1BB в ткани опухоли у пациентов с колоректальным раком превышала данный показатель группы контроля в 2,06раза и группы больных с доброкачественными новообразованиями в 1,43раза. Заключение. Сигнальный путь 4-1BB/4-1BBL вовлечен в каскад реакций врожденного и адаптивного иммунитета и является одним из звеньев канцерогенеза у больных с колоректальным...